Top Peptide Synthesis Companies

Peptide Synthesis Market size was valued at USD 791.12 Million in 2024 and is poised to grow from USD 893.97 Million in 2025 to USD 2376.57 Million by 2033, growing at a CAGR of 13% during the forecast period (2026–2033).

Key vendors in the Peptide Synthesis Market include Bachem Holding AG, CordenPharma International, Thermo Fisher Scientific Inc., Merck KGaA, GenScript Biotech Corporation, CSBio Company, Inc., AAPPTec LLC, Biotage AB, Syngene International Limited, and Aurigene Pharmaceutical Services Limited. These companies provide peptide synthesis products and services for pharmaceutical, biotechnology, and research applications, focusing on custom peptide manufacturing, advanced synthesis technologies, contract development and manufacturing (CDMO) services, and large-scale production of therapeutic peptides.

The key driver of the Peptide Synthesis Market is the increasing demand for peptide-based therapeutics in the treatment of cancer, metabolic disorders, infectious diseases, and rare diseases. Growing investments in pharmaceutical and biotechnology research, rising adoption of personalized medicine, and advancements in peptide synthesis technologies are driving market growth.

The key market trend in the Peptide Synthesis Market is the increasing adoption of automated and high-throughput peptide synthesis technologies to improve production efficiency, scalability, and product quality. Manufacturers are also expanding contract development and manufacturing (CDMO) services, integrating advanced solid-phase peptide synthesis techniques, and developing complex therapeutic peptides to support growing demand from pharmaceutical and biotechnology companies.

North America accounted for the largest share in the Peptide Synthesis Market due to its strong pharmaceutical and biotechnology industries, substantial investment in research and development, increasing demand for peptide-based therapeutics, and the presence of leading market players. The region also benefits from advanced healthcare infrastructure, robust clinical research activities, and favorable funding for drug discovery and development.